Deal Snapshot
Ovoca Bio Acquires Remaining 40% Interest in IVIX to Accelerate Development of Treatment for HSDD
Thursday 26 March 2020

Ireland-based women-focussed biopharmaceutical company Ovoca Bio has agreed to acquire the remaining 40% of shares in Russia-based IVIX LLC for a total cash consideration of RUB 354m (USD 5m), the company said.
Pursuant to the acquisition, Silver Star Ltd., Ovoca's wholly owned subsidiary, has acquired the interest that it does not already own directly in the charter capital of IVIX held by Bioprocess Capital Ventures.

Date Published: 26/03/2020